Gaps between Asian regulations for eligibility of human mesenchymal stromal cells as starting materials of cell therapy products and comparability of mesenchymal stromal cell-based products subject to changes in their manufacturing process

Working group 2 (WG2) of the Asia Partnership Conference of Regenerative Medicine has discussed eligibility of mesenchymal stromal cells (MSCs) as starting cells for the manufacture of cell therapy products, and comparability before and after changes in their manufacturing process. Asian countries a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Toshimitsu, Lee, Shing-Mou, Mikami, Mayu, Yokota, Kahori, Takakura, Koji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society for Regenerative Medicine 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770408/
https://www.ncbi.nlm.nih.gov/pubmed/33426228
http://dx.doi.org/10.1016/j.reth.2020.10.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770408/
https://www.ncbi.nlm.nih.gov/pubmed/33426228
http://dx.doi.org/10.1016/j.reth.2020.10.004

Ejemplares similares